Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Immobilized Anti-NCAM-1 Antibody, Human IgG1 at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human NCAM-1, Fc Tag (Cat. No. NC1-HF256) with a linear range of 0.08-0.625 μg/mL (QC tested).
The purity of Human NCAM-1 Protein, Llama IgG2b Fc Tag (Cat. No. NC1-H5254) is more than 90% and the molecular weight of this protein is around 245-285 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Rhabdomyosarcoma; Ovarian Neoplasms; Leukemia; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Sarcoma, Synovial; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Carcinoma, Small Cell | Details |
CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Rhabdomyosarcoma; Ovarian Neoplasms; Leukemia; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Sarcoma, Synovial; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Carcinoma, Small Cell | Details |
CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
This web search service is supported by Google Inc.